SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
October 23, 2003
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-19131 | 52-1555759 |
| (State or other jurisdiction of | (Commission File No.) | (I.R.S. Employer Identification No.) |
| incorporation or organization) |
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (301) 417-0770
Item 9. Regulation FD Disclosure.
On October 23, 2003, MedImmune, Inc. (the “Company”) issued a press release announcing the Company’s results for the three-month and nine-month periods ended September 30, 2003, and will conduct a previously announced publicly available conference call to discuss those results. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This information is being furnished pursuant to Items 9 and 12 of Form 8-K and is being presented under Item 9 of Form 8-K in accordance with interim guidance issued by the Securities and Exchange Commission in Release Nos. 33-8216 and 34-47583. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any registration statements filed under the Securities Act of 1933 or any report filed under the Securities Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIMMUNE, INC.
BY: /s/ Lota S. Zoth —————————————— Lota S. Zoth Vice President and Controller Principal Accounting Officer |
Dated: October 23, 2003
EXHIBIT INDEX
Exhibit 99.1 -- Press release, dated October 23, 2003, "MedImmune Reports Record Revenues for 2003 Third Quarter and Nine-Month Period"